Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $6,015,296.00 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 32,410 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $185.60, for a total value of $6,015,296.00. Following the transaction, the chief executive officer owned 7,229 shares in the company, valued at $1,341,702.40. The trade was a 81.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Herriot Tabuteau also recently made the following trade(s):

• On Monday, January 5th, Herriot Tabuteau sold 78,703 shares of Axsome Therapeutics stock. The shares were sold at an average price of $171.28, for a total transaction of $13,480,249.84.
• On Tuesday, January 6th, Herriot Tabuteau sold 29,450 shares of Axsome Therapeutics stock. The stock was sold at an average price of $172.33, for a total transaction of $5,075,118.50.
• On Wednesday, January 7th, Herriot Tabuteau sold 31,261 shares of Axsome Therapeutics stock. The stock was sold at an average price of $170.38, for a total transaction of $5,326,249.18.
• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The shares were sold at an average price of $148.18, for a total transaction of $1,564,484.44.
• On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The stock was sold at an average price of $144.59, for a total transaction of $7,121,346.68.
• On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The shares were sold at an average price of $146.94, for a total value of $2,962,751.22.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total value of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The stock was sold at an average price of $134.49, for a total value of $2,928,519.75.

Axsome Therapeutics Trading Down 1.0%

Shares of Axsome Therapeutics stock opened at $185.54 on Thursday. The stock has a market capitalization of $9.35 billion, a PE ratio of -39.73, a price-to-earnings-growth ratio of 12.09 and a beta of 0.40. Axsome Therapeutics, Inc. has a 52 week low of $86.99 and a 52 week high of $191.50. The stock has a 50 day moving average price of $165.41 and a two-hundred day moving average price of $137.44. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The firm had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. The company’s quarterly revenue was up 63.2% on a year-over-year basis. As a group, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axsome Therapeutics

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Axsome Therapeutics by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after buying an additional 235,626 shares during the last quarter. Wellington Management Group LLP raised its position in Axsome Therapeutics by 84.1% in the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after acquiring an additional 609,516 shares during the period. Invesco Ltd. boosted its stake in Axsome Therapeutics by 73.3% in the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock valued at $120,303,000 after acquiring an additional 419,008 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Axsome Therapeutics by 5.8% during the 2nd quarter. Geode Capital Management LLC now owns 989,453 shares of the company’s stock valued at $103,303,000 after acquiring an additional 54,600 shares during the period. Finally, State Street Corp grew its position in shares of Axsome Therapeutics by 5.8% during the 2nd quarter. State Street Corp now owns 958,503 shares of the company’s stock valued at $100,058,000 after acquiring an additional 52,483 shares during the period. 81.49% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AXSM. Jefferies Financial Group lifted their price objective on shares of Axsome Therapeutics from $200.00 to $245.00 and gave the company a “buy” rating in a report on Tuesday. Robert W. Baird set a $209.00 price target on Axsome Therapeutics in a research note on Tuesday, January 13th. Morgan Stanley lowered Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a report on Thursday, January 8th. HC Wainwright upped their price target on Axsome Therapeutics from $200.00 to $260.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $225.00 price objective on shares of Axsome Therapeutics in a research note on Monday, January 5th. Nineteen analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $208.72.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.